Alizyme licenses Colal-Pred to Norgine
This article was originally published in Scrip
Alizyme Therapeuticshas granted Norginethe exclusive rights to Colal-Pred (prednisolone sodium metasulfobenzoate), for the treatment of ulcerative colitis, in Europe, South Africa, Australia and New Zealand. Norgine will now develop and market Colal-Pred in the areas and will pay Alizyme €2 million up-front, with the possibility of milestone payments of up to €41 million. Norgine will cover all commercialisation costs and will pay double-digit royalty sales to Alizyme.